Cellectar Biosciences, Inc. (CLRB) Stock Score, Valuation & Financial Research

Cellectar Biosciences, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for CLRB

Cellectar Biosciences, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 1.51. These figures are a research snapshot, not a buy or sell recommendation.

What Cellectar Biosciences, Inc. does

Cellectar Biosciences is a biopharmaceutical firm engaged in the research, development, and market introduction of therapeutic agents to combat cancer. The company's primary asset is CLR 131 (iopofosine I-131), a phospholipid drug conjugate (PDC), which is currently undergoing several clinical evaluations. It is in Phase 2 clinical trials for individuals with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies. Additionally, CLR 131 is being studied in Phase 2B for r/r multiple myeloma (MM) and in Phase I trials targeting a range of pediatric cancers, r/r head and neck cancers, and R/R MM. Furthermore, Cellectar is advancing CLR 1900, another PDC-based chemotherapeutic program, which is in preclinical stages with the aim of treating solid tumors. The firm also participates in collaborative PDC development initiatives with partners such as Avicenna Oncology GMBH for the CLR 2000 Series, Orano Med for the CLR 12120 Series, as well as IntoCell Inc. and LegoChemBio. Established in 2002, Cellectar Biosciences maintains its corporate headquarters in Florham Park, New Jersey.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Cellectar Biosciences is a late-stage clinical biopharmaceutical company that generates no commercial revenue. Its business model relies on raising capital through equity offerings and potential future licensing or commercialization of its proprietary phospholipid drug conjugate (PDC) delivery platform and pipeline candidates.

Products and services

  • The company develops phospholipid drug conjugates (PDCs) for cancer treatment, including lead programs iopofosine I 131, CLR 125, and CLR 225.

Suppliers, materials and equipment

  • Nusano — Supplier of iodine-125 and actinium-225 isotopes. Source

Business relationships and partnerships

  • Nusano — A long-term multi-isotope supply agreement to provide iodine-125 and actinium-225 for clinical studies. Source

Business strengths to evaluate

  • Proprietary phospholipid drug conjugate (PDC) delivery platform Source

Business risks and research considerations

  • History of operating losses and expectation of continued losses Source
  • Need for additional capital to fund operations and clinical trials Source

Sources: Company research source · Nusano

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

CLRB financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 1.51
Market capitalization:
12.06M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -22.32M
Free cash flow:
USD -23.12M
Cash:
USD 33.99M
Total debt:
USD 1.53M
EPS:
USD -4.56

What stands out

  • Free cash flow is USD -23.12M, negative for the stored period.
  • The balance sheet shows USD 33.99M of cash versus USD 1.53M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 32.46M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for CLRB

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can CLRB fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is CLRB likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for CLRB to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of CLRB's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research CLRB

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.